Skip to content

Regenxbio RGNX Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$661.6M-21.8%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
-$84.99M-87.6%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$105.91M-22.2%
Xencor logo
XencorXNCR
-$130.47M-175%
Biogen logo
BiogenBIIB
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN

Other financials

Income statement

See full
Revenue$6.4M-92.8%
Gross profit$14.9M+35.7%
Operating income-$83.4M-787%
Net income-$90.1M-1,580%
EPS (diluted)-$1.72-1,533%

Balance sheet

See full
Cash & equivalents$15.2M-88.3%
Total debt$71.1M-11.0%
Total equity$21.1M-92.3%
Total assets$341.9M-30.4%

Cash flow

See full
Operating cash flow-$76.2M-327%
CapEx$1.2M+20.6%
Free cash flow-$77.4M-337%

Valuation

See full
Market cap$529.38M+24.6%
Enterprise value$585.22M+56.3%
P/S+3.3×

Profitability

See full
Gross margin59.7%+1.0pp
Operating margin-292.3%-613pp
Net margin-330.2%-588pp
FCF margin-269.2%-364pp

Returns & leverage

See full
Return on equity-196.4%-288pp
Debt / equity3.4×+3.1×
Current ratio2.6×-0.3×

Where this comes from

Reported directly by Regenxbio in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The official record: Regenxbio’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regenxbio's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Regenxbio's comprehensive income (loss), net of tax, attributable to parent?
Regenxbio (RGNX) reported comprehensive income (loss), net of tax, attributable to parent of -$90.23M in Q1 2026.
How has Regenxbio's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Regenxbio's comprehensive income (loss), net of tax, attributable to parent decreased by 1588.5% year-over-year, from $6.06M to -$90.23M.
What is the long-term trend for Regenxbio's comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Regenxbio's comprehensive income (loss), net of tax, attributable to parent has grown at a 11.4% compound annual growth rate (CAGR), from $125.63M to -$193.82M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This is the final measure of a company's total financial performance, combining net income with other comprehensive income items. It represents the total change in equity from non-owner sources during the reporting period. Investors use this to evaluate the comprehensive impact of all financial activities, including market-driven fluctuations, on the company's net worth.